Immuno-Oncology | Specialty

Neoadjuvant Tislelizumab Plus Chemo Drives Responses in Locally Advanced Cervical Cancer

September 15th 2025

Neoadjuvant tislelizumab plus chemotherapy yielded responses in locally advanced cervical cancer.

Five Under 5: Top Oncology Videos for the Week of 8/31

September 7th 2025

The top 5 OncLive videos of the week cover insights in sarcoma, colorectal cancer, acute lymphoblastic leukemia, renal cell carcinoma.

The OncFive: Top Oncology Articles for the Week of 8/31

September 6th 2025

FDA grants type A meeting to discuss RP1 BLA in melanoma, CBP/p300 bromodomain inhibitor gets fast track status in NSCLC, and more.

VAX014 Demonstrates Safety, Early Signs of Immune-Mediated Activity in Advanced Solid Tumors

September 5th 2025

EU Approves MMR IHC Panel pharmDx as a Companion Diagnostic for Nivolumab/Ipilimumab in MSI-H/dMMR CRC

September 3rd 2025

The MMR IHC Panel pharmDx was certified in the EU as a companion diagnostic to identify patients with colorectal cancer eligible for nivolumab/ipilimumab.

OncLive’s August Roundup of Key FDA Approvals in Oncology: 3 Decisions to Know

September 2nd 2025

Here is your guide to all therapeutic options that were cleared by the FDA in August 2025 spanning tumor types.

Oncology Conferences to Watch in the Second Half of 2025

August 20th 2025

Upcoming oncology meetings in the second half of 2025 will present new data across tumor types and offering updates that may influence standards of care.

Magrolimab/Nivolumab Combos Drive Responses in Unresectable Advanced/Recurrent CRC

August 19th 2025

Magrolimab plus nivolumab and FOLFOX with bevacizumab or cetuximab yielded responses in advanced/recurrent colorectal cancer.

The OncFive: Top Oncology Articles for the Week of 8/10

August 16th 2025

Vepdegestrant NDA under FDA review in ESR1-mutated breast cancer, Oncomine Dx Target Test gets greenlit as zongertinib companion diagnostic in NSCLC.

Immunotherapy and T-Cell–Directed Therapy Expand Treatment Approaches in Small Cell Lung Cancer

August 14th 2025

Sonam Puri, MD, discusses advances in small cell lung cancer that have expanded treatment options across disease stages.

Unmet Needs Research Aims to Address in Early-Stage NSCLC

August 14th 2025

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss ongoing research in early-stage non–small cell lung cancer.

Encorafenib Triplet Could Address Poor Outcomes With Immunotherapy in BRAF V600–Mutant Melanoma With Brain Metastases

August 13th 2025

Zeynep Eroglu, MD, discusses the potential PFS benefit with encorafenib plus binimetinib and nivolumab in BRAF V600–mutant melanoma with symptomatic brain metastases.

How Chemoimmunotherapy, PRRT, and First-Line Immunotherapy Are Reshaping GI Cancer Management

August 12th 2025

Tanios S. Bekaii-Saab, MD, discusses evolving frontline and evolving treatment strategies in esophageal cancer, HCC, and NETs.

How Immunotherapy Could Continue to Affect Early-Stage NSCLC Management

August 7th 2025

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss how immunotherapy could continue to reshape early NSCLC management.

Factors Influencing Adjuvant Treatment Decisions in Early-Stage NSCLC

August 7th 2025

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss factors that affect adjuvant treatment decisions in early non–small cell lung cancer.

FDA Outlines Next Steps for Development of Eftilagimod Alfa in PD-L1–Negative HNSCC

August 5th 2025

The FDA provided feedback on next steps of development for eftilagimod alfa in PD-L1–negative recurrent/metastatic head and neck squamous cell carcinoma.

Retrospective Data Show Feasibility of Checkpoint Inhibition in Patients With Cancer and Neurologic Autoimmune Disorders

August 4th 2025

A retrospective study showed immune checkpoint inhibitors may be an option in appropriate indications for patients with neurologic autoimmune disorders.

Final Phase 3 Data Underscore Role of Pembrolizumab/Chemoradiotherapy in High Risk, Locally Advanced Cervical Cancer

August 1st 2025

Linda Duska, MD, MPH, discusses final results of KEYNOTE A18 for pembrolizumab plus chemoradiotherapy in high risk, locally advanced cervical cancer.

Close Collaboration Between Oncology and Neurology Vital in Managing Patients With NAIDs Receiving ICIs for Cancer

July 31st 2025

Shailee S. Shah, MD, discusses the frequency and severity of neurologic autoimmune disorder exacerbation in patients with cancer receiving ICIs.

Biomarkers May Inform Potential Role for Ipilimumab/Nivolumab in Untreated Metastatic Urothelial Cancer After Missing OS End Point

July 30th 2025

Guru P. Sonpavde, MD, discusses the role of ipilimumab/nivolumab after negative trial results in managing advanced urothelial cancer.